
Seer, Inc. — Investor Relations & Filings
Seer, Inc. is a life sciences company that develops and commercializes products to advance proteomics research. The company's core offering is the Proteograph Product Suite, an integrated platform designed to provide deep, unbiased, and large-scale access to the proteome. Utilizing proprietary engineered nanoparticles, Seer's technology enables researchers to analyze complex biological samples with high throughput, speed, and reproducibility. This approach facilitates the comprehensive detection of proteins, including those at low abundance that are critical for understanding disease and health states. The platform is complemented by the Proteograph Analysis Suite, a software solution for data analysis and biomarker discovery. Seer aims to empower the scientific community with tools to overcome technological barriers in proteomics, accelerating insights in precision medicine and human biology.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEFA14A | 2026-05-22 | English | |
| DEFA14A | 2026-05-22 | English | |
| 8-K | 2026-05-22 | English | |
| 10-Q - Seer, Inc. (0001726445) (Filer) | 2026-05-13 | English | |
| 10-K/A - Seer, Inc. (0001726445) (Filer) | 2026-04-30 | English | |
| DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-29 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46819500 | DEFA14A | 2026-05-22 | English | ||
| 46818766 | DEFA14A | 2026-05-22 | English | ||
| 46818054 | 8-K | 2026-05-22 | English | ||
| 45764677 | 10-Q - Seer, Inc. (0001726445) (Filer) | 2026-05-13 | English | ||
| 39212809 | 10-K/A - Seer, Inc. (0001726445) (Filer) | 2026-04-30 | English | ||
| 38584983 | DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-29 | English | ||
| 36141962 | DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-24 | English | ||
| 34439529 | 8-K - Seer, Inc. (0001726445) (Filer) | 2026-04-13 | English | ||
| 34439493 | DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-13 | English | ||
| 32897348 | 10-K - SEER, INC. (0001726445) (Filer) | 2026-03-02 | English | ||
| 32897347 | 8-K - SEER, INC. (0001726445) (Filer) | 2026-02-26 | English | ||
| 32897346 | 8-K - SEER, INC. (0001726445) (Filer) | 2026-02-26 | English | ||
| 32897344 | 4 - SEER, INC. (0001726445) (Filer) | 2026-02-19 | English | ||
| 32897345 | 4 - SEER, INC. (0001726445) (Filer) | 2026-02-19 | English | ||
| 31497902 | 4 Filing | 2026-02-05 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
NOVOPROTEIN SCIENTIFIC INC.
Develops recombinant proteins and enzymes for life sciences…
|
688137 | CN | Professional, scientific and te… |
|
NOXOPHARM LIMITED
Clinical-stage developer of novel treatments for cancer and…
|
NOX | AU | Professional, scientific and te… |
|
NUFORMIX PLC
Pharmaceutical developer using cocrystal technology to repu…
|
NFX | GB | Professional, scientific and te… |
|
Nurix Therapeutics, Inc.
Clinical-stage biopharma developing protein degradation the…
|
NRIX | US | Professional, scientific and te… |
|
NYRADA INC.
Develops small molecule therapeutics for cardiovascular hea…
|
NYR | AU | Professional, scientific and te… |
|
OLIPASS CORPORATION
An R&D company developing RNA therapeutics using its propri…
|
244460 | KR | Professional, scientific and te… |
|
OmniAb, Inc.
A technology platform for therapeutic antibody discovery us…
|
OABIW | US | Professional, scientific and te… |
|
ONCIMMUNE HOLDINGS PLC
Immunodiagnostics company specializing in antibody and auto…
|
ONC | GB | Professional, scientific and te… |
|
Oncocross Co.,Ltd.
An AI biotechnology firm that develops drugs by predicting …
|
382150 | KR | Professional, scientific and te… |
|
ONCODESIGN
Develops therapeutic and diagnostic solutions for resistant…
|
ALONC | FR | Professional, scientific and te… |
Seer, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34036/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34036 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34036 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34036 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34036}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Seer, Inc. (id: 34036)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.